|1.||Nave, Ruediger: 3 articles (01/2007 - 05/2005)|
|2.||Nave, R: 2 articles (03/2007 - 01/2006)|
|3.||Sato, Hideyuki: 2 articles (01/2007 - 01/2007)|
|4.||Kondo, Shiro: 2 articles (01/2007 - 01/2007)|
|5.||Takahama, Shigehiro: 2 articles (01/2007 - 01/2007)|
|6.||Nonaka, Takashi: 2 articles (01/2007 - 01/2007)|
|7.||Mochizuki, Tsutomu: 2 articles (01/2007 - 01/2007)|
|8.||Shaik, Jafar Bhasha: 1 article (05/2013)|
|9.||Ahlawat, Preeti: 1 article (05/2013)|
|10.||Srinivas, Nuggehally R: 1 article (05/2013)|
|1.||Asthma (Bronchial Asthma)
10/01/2010 - "The objectives of this study were to characterize pharmacokinetics (PK) and pharmacodynamics (PD) of FP and a pharmacologically active metabolite of CIC (desisobutyryl-ciclesonide [Des-CIC]) using a nonlinear mixed-effects modeling approach, to investigate selected covariate effects on PK and PD parameters of FP and Des-CIC, and to assess the systemic effects of FP and CIC on serum cortisol suppression in patients with persistent asthma. "
05/01/2013 - "Ciclesonide, a novel glucocorticosteroid, through a rapid metabolism to desisobutyryl-ciclesonide (des-ciclesonide), provides an effective treatment option for asthma episodes by the inhaled route of administration. "
01/01/2006 - "To evaluate whether the inflammatory process and bronchial constriction associated with asthma influence the pulmonary distribution and airway penetration of inhaled ciclesonide by investigating the pharmacokinetics of ciclesonide and its active metabolite, desisobutyryl-ciclesonide (des-CIC) in patients with asthma and matched healthy subjects. "
01/01/2006 - "Pharmacokinetic disposition of inhaled ciclesonide and its metabolite desisobutyryl-ciclesonide in healthy subjects and patients with asthma are similar."
05/01/2005 - "Desisobutyryl-ciclesonide (des-CIC) is the active metabolite of ciclesonide, an effective, novel ICS for persistent asthma. "
01/01/2007 - "The nasal tissue uptake and metabolism of ciclesonide, a new-generation corticosteroid under investigation for treatment of allergic rhinitis, to its active metabolite, desisobutyryl-ciclesonide (des-CIC), was evaluated when administered to rabbits in a hypotonic versus an isotonic ciclesonide suspension. "
03/01/2007 - "Ciclesonide, a new corticosteroid for allergic rhinitis, is administered as an inactive parent compound that is converted by esterases to the pharmacologically active metabolite, desisobutyryl-ciclesonide (des-CIC). "
01/01/2007 - "Ciclesonide, a corticosteroid in development for allergic rhinitis, is converted to the pharmacologically active metabolite, desisobutyryl-ciclesonide (des-CIC), and des-CIC is subsequently esterified with fatty acids. "
|3.||Fatty Acids (Saturated Fatty Acids)